EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus

Julius Lindblom1,2, Alvaro Gomez1,2, Alexander Borg1,2, Sharzad Emamikia1,2, Dimitris Ladakis1,2, Joaquin Matilla1,2, Martin Pehr1,2, Flordelyn Cobar1,2, Yvonne Enman1,2, Emelie Heintz3, Malin Regardt4,5, Ioannis Parodis1,2

1 Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
2 Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
3 Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden
4 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
5 Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden

Correspondence to: Ioannis Parodis | MD PhD
Address: Rheumatology, Karolinska University Hospital, SE-171 76, Stockholm
E-mail: ioannis.parodis@ki.se
ORCiD iD: 0000-0002-4875-5395
Abstract

Objectives: To investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and identify factors associated with FHS after treatment.

Methods: Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belimumab (N=1684) were utilised. FHS was defined as a response of no problems in all five EQ-5D-3L dimensions, yielding an index score of 1. The Pearson’s chi-square or Fisher’s exact test was employed for comparisons, and logistic regression for adjustments and assessment of independence.

Results: We demonstrated higher EQ-5D-3L FHS frequencies among patients given standard therapy (ST) plus the licensed belimumab dose versus ST alone (26.1% versus 19.4%; P=0.001; week 52), and within SRI-4 responders versus non-responders (27.0% versus 19.8%; P<0.001; week 52) from week 36 to 52. In multivariable regression analysis, SLEDAI-2K (OR: 0.90; 95% CI: 0.87–0.94; P<0.001) and SLICC/ACR Damage Index (OR: 0.79; 95% CI: 0.69–0.91; P=0.001) scores were independently associated with lower FHS frequencies at week 52, while adding monthly infusions of belimumab 10 mg/kg to ST favoured FHS perception (OR: 1.60; 95% CI: 1.15–2.24; P=0.006). Add-on belimumab 10 mg/kg yielded higher FHS frequencies in antimalarial users versus non-users (29.9% versus 20.1%; P=0.011), and in anti-dsDNA and anti-Sm positive versus negative patients (31.4% versus 13.4%; P<0.001 and 33.0% versus 22.6%; P=0.010, respectively), whereas no significant differences were observed in patients given ST alone.

Conclusion: EQ-5D-3L FHS distinguished belimumab from placebo and responders from non-responders, and exhibited known-group validity in subgroup analysis. FHS may prove a useful patient-reported outcome in SLE studies.
**Keywords:** systemic lupus erythematosus; health-related quality of life; patient-reported outcomes; patient perspective; outcomes research

**Key messages**

- EQ-5D-3L full health state discriminated belimumab from placebo and responders from non-responders in SLE RCTs.
- Add-on belimumab yielded greater EQ-5D-3L FHS frequencies in anti-dsDNA and anti-Sm positive versus negative patients.
- Concomitant use of antimalarials enhanced the benefit from belimumab to yield EQ-5D-3L full health state.

**Introduction**

SLE is a chronic autoimmune disease with detrimental effects on patients’ health-related quality of life (HRQoL) [1]. Patient-reported HRQoL outcomes gain increasing endorsement within the SLE researcher community, as well as in routine care as a complemental part of the clinical evaluation [2]. This marks a paradigm shift towards patient-centred care, from a historical negligence of the patient’s perspective.

During the OMERACT IV consensus conference [3], four important core outcomes for SLE clinical trials were ratified, i.e. disease activity, HRQoL, medication side-effects, and organ damage, in that priority order. The known discordance in perceptions of disease activity between physicians and SLE patients [4] further justifies the use of patient-reported outcome measures (PROMs). Indeed, PROMs are increasingly used in SLE clinical trials [2]. The Medical Outcomes Survey Short Form 36 (SF-36) [5] and Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-F) [6] were reviewed for their psychometric properties
according to guidance by the US Food and Drug Administration (FDA) [7], under the auspices of the OMERACT SLE working group, and are suggested as secondary endpoints to support labelling claim for novel SLE therapies [8]. Changes in scores in various SF-36 domains and FACIT-F have shown ability to discriminate between belimumab and placebo in the BLISS-52 and BLISS-76 clinical trials [9]. In the same analysis, changes in index scores of the EuroQol 5-Dimension health questionnaire (EQ-5D) [10] did not exhibit discriminative ability. However, EQ-5D has been shown to have satisfactory psychometric properties for SLE patients in terms of validity and reliability [11], justifying further study on the discriminative ability of EQ-5D in clinical trials applying alternative derivates to its index score.

EQ-5D is a widely used generic instrument for the assessment of HRQoL, with its short format contributing to its popularity. It consists of a visual analogue scale intended to reflect overall health status, and a descriptive system comprising five questions, each denoting one dimension of health. Responses from no to major problems in these five questions can be presented in a health profile and be summarised in an index score, which is calculated based on population-specific scoring algorithms. This score may range from less than 0 to 1. Response of “no problems” in all five dimensions, termed full health state (FHS), equals to an EQ-5D index score of 1 and is intended to reflect the desired perception of health status [12].

The aim of this study was to investigate the discriminative ability of EQ-5D FHS in two phase III clinical trials of SLE. More specifically, we investigated the ability of EQ-5D FHS to distinguish belimumab plus standard therapy (ST) from ST alone, and responders from non-responders. Furthermore, we sought to determine factors that were associated with EQ-5D FHS after the trial intervention.

**Patients and methods**
Study design and population

We performed a post-hoc analysis of data from BLISS-52 (NCT00424476) [13] and BLISS-76 (NCT00410384) [14], two multicentre phase III clinical trials of belimumab with similar design and endpoints. BLISS-52 comprised 865 participants from 13 countries in Latin America, Asia Pacific and Eastern Europe, whereas BLISS-76 enrolled 819 participants from 19 countries in Europe and North/Central America (see list of countries in Supplementary Table S1), all fulfilling the ACR revised criteria for SLE [15]. All patients were ≥18 years of age, had an ANA titre ≥1:80 and/or serum anti-dsDNA antibody level ≥30 IU/mL, and a Safety of Estrogens in Lupus National Assessment-SLEDAI (SELENA-SLEDAI) [16] score ≥6.

All patients were on stable ST for ≥30 days before baseline; this could include glucocorticoids, antimalarial agents (AMA), and immunosuppressants. Patients were randomised to receive belimumab 1 mg/kg, belimumab 10 mg/kg, or placebo as intravenous infusions at week 0, 2, 4, and thereafter every fourth week until week 48 in BLISS-52 and until week 72 in BLISS-76, in addition to ST, with a final assessment at week 52 and 76, respectively.

Longitudinal data from BLISS-52 and BLISS-76, including registrations of the three-level version of EQ-5D (EQ-5D-3L), were made available by GlaxoSmithKline (Uxbridge, UK) through the Clinical Study Data Request (CSDR) consortium. To manage missing values, the last observation was carried forward for all variables except for BMI, for which the mean weight of the previous and next available visits was used in the BMI formula and the last observation was carried forward when values from the last visits were missing. The total number of patients with available EQ-5D-3L data at week 52 was 1665 in the pooled study population.
The study complied with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study protocol for the present post-hoc analysis was approved by the Swedish Ethical Review Authority (2019-05498).

Clinical and laboratory data

SLE disease activity was assessed using the SLEDAI-2K [17], and organ damage using the SLICC/ACR Damage Index (SDI) [18]. The primary endpoint of the BLISS-52 and BLISS-76 trials, i.e. attainment of SLE Responder Index 4 (SRI-4) [19] at week 52, denoted responders.

Serum levels of anti-dsDNA \( \geq 30 \) IU/mL, anti-Smith (Sm) \( \geq 15 \) U/mL, anti-ribosomal P protein \( >25 \) EU/mL, aCL IgA \( \geq 15 \) APL U/mL, aCL IgG \( \geq 10 \) GPL U/mL, and aCL IgM \( \geq 10 \) MPL U/mL determined positivity. Levels of complement component 3 (C3) \( <0.9 \) g/L and complement component 4 (C4) \( <0.16 \) g/L were considered low.

EQ-5D-3L full health state

The descriptive system of EQ-5D-3L incorporates five HRQoL dimensions, i.e. self-care, mobility, usual activities, pain/discomfort, and anxiety/depression. Respondents may report no problems (level 1), some/moderate (level 2), or extreme/major problems (level 3) in each one of these dimensions. As per the EQ-5D-3L user guide, we defined FHS as a response of no problems in all five dimensions, hence an EQ-5D-3L index score equal to 1 [12], and calculated its frequency in patient subgroups at multiple study visits. We compared EQ-5D-3L FHS frequencies between treatment arms and between SRI-4 responders and non-responders to determine the discriminative ability of this PROM in two a priori known successful trials, both demonstrating superiority of belimumab over placebo to yield SRI-4 response. While the comparisons between treatment arms mainly served to assess the discriminative ability of EQ-
5D-3L FHS to inform future clinical trial design, the comparisons between SRI-4 responders and non-responders mainly served for known-group validity analysis. Apart from responders versus non-responders, we compared EQ-5D-3L FHS perception in a priori distinct groups in a subsequent subgroup analysis.

For the purpose of comparison with the general population, we created a US civilian non-institutionalised population-based reference group (N=1665), individually matched for age and sex with the study participants, with distributions of FHS corresponding to the last one of three possible registrations in the Medical Expenditure Panel Survey (MEPS) [20] between 2000 and 2002. MEPS respondents’ EQ-5D-3L index score and FHS distributions stratified by age category and sex are presented as Supplementary Data.

Statistics

Data are presented as number (percentage) or mean ± standard deviation (SD) and in case of non-normal distributions, the median (interquartile range) is indicated. The Mann-Whitney U test was used for comparisons of unrelated continuous data, and the Pearson’s chi-square or Fisher’s exact test was used for associations between unrelated binomial variables, as appropriate. The McNemar’s test was used for comparisons of FHS proportions between SLE patients and individually matched comparators. Logistic regression analysis was employed to adjust for baseline status in comparisons between treatment arms or responders versus non-responders. For determination of factors associated with EQ-5D-3L FHS at week 52, univariable logistic regression analysis guided the selection of variables to be used in subsequent multivariable logistic regression analysis.
P values <0.05 were considered statistically significant. Analyses were performed using the IBM SPSS software version 26 (IBM Corp., NY, USA). The GraphPad Prism 7 (GraphPad Software Inc., CA, USA) was used for the construction of graphs.

Patient involvement

Patient research partners were involved in the study concept and design, interpretation of data, and editing of the manuscript.

Results

Patient characteristics and clinical data for the pooled BLISS population are presented in Table 1, including comparisons between patients reporting EQ-5D-3L FHS and patients not experiencing FHS at the evaluation of week 52. Greater proportions of patients given belimumab 10 mg/kg plus ST (37.6% versus 31.8%; P=0.035) and lower proportions of patients who received ST alone (28.2% versus 35.1%; P=0.012) were seen among FHS respondents (Table 1). Corresponding data for the BLISS-52 and BLISS-76 trial populations are presented in Supplementary Table S2 and Supplementary Table S3, respectively.

Notably, the frequency of FHS at week 52 in the pooled BLISS study population (23.0%; N=383) was 52.8% lower than among age- and sex-matched US population-based EQ-5D-3L respondents (48.7%; N=811; odds ratio, OR: 0.63; 95% CI: 0.58–0.69; P<0.001).

Discriminative ability

Proportions of patients reporting FHS from baseline through week 52 are delineated in Figure 1, including stratifications by treatment arm and BLISS study. At week 52, the
frequency of FHS was 23.0% in the pooled BLISS study population (Figure 1A; Supplementary Table S4), 28.1% in BLISS-52 (Figure 1B; Supplementary Table S5), and 17.7% in BLISS-76 (Figure 1C; Supplementary Table S6).

In the pooled BLISS study population, higher proportions of patients within the belimumab 10 mg/kg plus ST arm reported EQ-5D-3L FHS compared with patients given ST alone from week 36 through week 52, with a proportion of 26.1% versus 19.4% at week 52 (adjusted OR: 1.73; 95% CI: 1.26–2.37; P=0.001; Figure 1A). A separation of similar magnitude was observed at week 52 in the BLISS-52 (31.9% versus 25.4%; OR: 1.53; 95% CI: 1.01–2.31; P=0.043; Figure 1B) and BLISS-76 (20.1% versus 13.1%; OR: 2.10; 95% CI: 1.26–3.50; P=0.005; Figure 1C) study populations.

As shown in Figure 2A and Supplementary Table S7, FHS also discriminated between SRI-4 responders and non-responders from week 36 through week 52 in the pooled BLISS study population, yielding a proportion of 27.0% at week 52 for responders and 19.8% for non-responders (adjusted OR: 1.75; 95% CI: 1.35–2.26; P<0.001). Similarly, a higher proportion of SRI-4 responders versus non-responders reported FHS at week 52 in BLISS-52 (31.1% versus 25.2%; OR: 1.63; 95% CI: 1.16–2.28; P=0.005; Figure 2B; Supplementary Table S8) and in BLISS-76 (21.6% versus 15.2%; OR: 1.75; 95% CI: 1.18–2.62; P=0.006; Figure 2C; Supplementary Table S9).

**Discriminative ability of level 1 response within each EQ-5D dimension**

Proportions of patients reporting no problems (level 1) at week 52 within each one of the five EQ-5D dimensions across the three treatment arms are delineated in Figure 3A (see also online Supplementary Table S10). Higher proportions of patients reported EQ-5D-3L level 1 within the belimumab 10 mg/kg arm than among patients in the placebo arm with regard to
mobility (68.5% versus 62.5%; OR: 1.32; 95% CI: 1.00–1.74; P=0.049), self-care (84.8% versus 81.2%; OR: 1.46; 95% CI: 1.02–2.10; P=0.038) and pain/discomfort (34.1% versus 27.8%; OR: 1.51; 95% CI: 1.14–1.99; P=0.004), and within the belimumab 1 mg/kg arm versus placebo with regard to mobility (68.5% versus 62.5%; OR: 1.45; 95% CI: 1.10–1.92; P=0.009), self-care (84.7% versus 81.2%; OR: 1.48; 95% CI: 1.03–2.13; P=0.035) and anxiety/depression (56.4% versus 49.8%; OR: 1.34; 95% CI: 1.03–1.75; P=0.031).

As shown in Figure 3B (see also online Supplementary Table S11), higher proportions of SRI-4 responders than non-responders reported level 1 in all five EQ-5D dimensions.

**Factors associated with EQ-5D-3L FHS after therapeutic intervention**

Results from the initial univariable logistic regression analysis are shown in Supplementary Table S12. In the subsequent multivariable logistic regression model (Figure 4; Supplementary Table S13), FHS at baseline yielded a 10-fold higher probability of FHS perception at week 52 than non-FHS at baseline (OR: 10.01; 95% CI: 7.07–14.17; P<0.001). Female sex (OR: 0.56; 95% CI: 0.33–0.92; P=0.023) and increasing BMI (OR: 0.96; 95% CI: 0.94–0.99; P=0.006) were independently negatively associated with FHS, as were increasing SLEDAI-2K (OR: 0.90; 95% CI: 0.87–0.94; P<0.001) and SDI (OR: 0.79; 95% CI: 0.69–0.91; P=0.001) scores at week 52. Notably, anti-dsDNA positivity at baseline (OR: 2.23; 95% CI: 1.58–3.15; P<0.001) predicted FHS at week 52. Lastly, addition of belimumab 10 mg/kg to ST (OR: 1.60; 95% CI: 1.15–2.24; P=0.006) independently favoured FHS compared with ST alone.

**EQ-5D-3L FHS as a PROM denoting belimumab efficacy in subgroup analysis**

Demographics and clinical data of EQ-5D-3L FHS versus non-FHS respondents are also presented separately for the patient populations of the placebo (Supplementary Table S14),
belimumab 1 mg/kg (Supplementary Table S15) and belimumab 10 mg/kg (Supplementary Table S16) arms. Based on these results, FHS frequencies at week 52 in the entire BLISS population and the belimumab 10 mg/kg and placebo patient subgroups were next plotted in Figure 5 to illustrate differences between groups in selected variables. A lower proportion of women (22.3%) versus men (33.3%; OR: 0.58; 95% CI: 0.37–0.89; \(P=0.012\)) reported FHS (Figure 5A) in the entire population, with this difference being more prominent in the placebo group (18.1% versus 35.0%; OR: 0.41; 95% CI: 0.21–0.82; \(P=0.009\)). Belimumab 10 mg/kg showed superiority over placebo within the female population, with 26.3% versus 18.1% women reporting FHS at week 52 (OR: 1.95; 95% CI: 1.39–2.73; \(P<0.001\)). A similar benefit from belimumab 10 mg/kg was also seen for African Americans (20.0% versus 6.0%; OR: 4.50; 95% CI: 1.06–19.13; \(P=0.042\); Figure 5B). In the entire population, the frequency of FHS was lower among patients with SDI scores >0 at week 52 (15.7%) compared with patients with zero SDI scores (28.9%; OR: 0.46; 95% CI: 0.36–0.58; \(P<0.001\); Figure 5C). Importantly, while belimumab 10 mg/kg plus ST was superior over ST alone in favouring FHS after the trial intervention both in patients with zero SDI scores (31.7% versus 24.2%; OR: 1.29; 95% CI: 1.06–1.56; \(P=0.010\)) and patient with SDI scores >0 (18.5% versus 13.5%; OR: 1.35; 95% CI: 1.01–1.80; \(P=0.045\)), a higher frequency of FHS was seen among patients with zero SDI scores treated with belimumab 10 mg/kg (OR: 2.05; 95% CI: 1.36–3.07; \(P<0.001\)).

Within the entire BLISS population, a higher proportion of SLE patients who were anti-dsDNA positive at baseline reported FHS at week 52 (26.9%) than did anti-dsDNA negative patients (14.3%; OR: 2.20; 95% CI: 1.67–2.92; \(P<0.001\); Figure 5D). Similarly, a higher proportion of anti-dsDNA positive patients within the belimumab 10 mg/kg group reported FHS at week 52 (31.4%) compared with anti-dsDNA negative patients (13.4%; OR: 2.96; 95% CI: 1.80–4.87; \(P<0.001\)), but no such difference between anti-dsDNA positive and negative patients was seen within the placebo group (21.5% versus 14.8%; OR: 1.58; 95% CI: 0.98–2.54;
Additionally, a higher proportion of anti-dsDNA positive patients given belimumab 10 mg/kg plus ST experienced FHS at week 52 (31.4%) than did anti-dsDNA positive patients who received ST alone (21.5%; OR: 1.95; 95% CI: 1.35–2.80; P<0.001). Interestingly, a similar pattern was seen for anti-Sm (Figure 5E).

While no difference in EQ-5D-3L FHS frequencies was found in the entire BLISS population or the belimumab 10 mg/kg group between aCL IgM positive and negative patients (Figure 5F), a lower proportion of aCL IgM positive patients reported FHS within the placebo group (3.7% versus 20.2%; OR: 0.15; 95% CI: 0.02–1.14; P=0.035; P=0.063 after continuity correction). Notably, a higher proportion of AMA users (25.0%) versus non-users (19.5%; OR: 1.38; 95% CI: 1.08–1.76; P=0.010) reported FHS in the entire population and the belimumab 10 mg/kg group (29.9% versus 20.1%; OR: 1.70; 95% CI: 1.13–2.55; P=0.011), but not in the placebo group (Figure 5G). Finally, a higher FHS frequency was seen among AMA users who were also given belimumab 10 mg/kg (29.9%) compared with AMA users who received placebo (21.4%; OR: 1.84; 95% CI: 1.26–2.71; P=0.002).

**Discussion**

Despite a 52-week long therapeutic intervention, patients with SLE were herein shown to report FHS in EQ-5D-3L 52.8% less frequently than individuals in the general US population, corroborating the known detrimental impact of SLE on HRQoL [1]. EQ-5D-3L FHS displayed ability to discriminate between belimumab 10 mg/kg plus ST and ST alone in the SLE populations of the BLISS-52 and BLISS-76 trials. Furthermore, FHS also distinguished SRI-4 responders from non-responders. Addition of belimumab 10 mg/kg to ST especially favoured FHS after the trial intervention in anti-dsDNA and anti-Sm positive patients, and concomitant AMA use enhanced the benefit from belimumab to yield FHS perception.
Several findings in the present investigation provide additional support for satisfactory psychometric properties of EQ-5D-3L, full health state (i.e. EQ-5D-3L index score 1) in particular. In the concrete, EQ-5D-3L FHS exhibited discriminative potentiality and clinically relevant properties. First, despite the stringent requirement for a “no problem” response in all five EQ-5D-3L dimensions, FHS was more frequently reported than clinical outcomes intended to reflect low disease activity or remission, such as the Lupus Low Disease Activity State (LLDAS) [21-23] and Definitions of Remission in SLE (DORIS) [24, 25], in the same trials. Second, FHS showed ability to discriminate between belimumab 10 mg/kg plus ST and ST alone from week 36 onwards in the pooled BLISS study population, and at multiple time points in the BLISS-52 and BLISS-76 trial populations when analysed separately. Third, EQ-5D-3L FHS also showed ability to separate SRI-4 responders from non-responders, and high disease activity and organ damage scores were both negatively associated with FHS after the trial intervention. In light of conflicting data in the literature regarding the relationship between self-perception of HRQoL and disease activity or damage features, with some studies reporting modest negative associations [26-29] and some other demonstrating no interrelationship [30-32], our latter findings support the notion that EQ-5D-3L FHS incorporates patient perceptions of HRQoL that yield good congruence with well-established clinical parameters. Collectively, these findings suggest that EQ-5D-3L FHS may prove a useful PROM in SLE studies, and aspire to inform future clinical trial design.

PROMs of HRQoL such as SF-36 and FACIT-F have been shown to be sensitive to change along with clinical response, and have also been reported to discriminate between treatment arms in several SLE trials [8]. In fact, belimumab plus ST yielded greater changes than ST alone in several domains of SF-36 and in FACIT-F scores in the BLISS-52 and BLISS-76 trials [9, 33], which however was not the case for EQ-5D-3L index scores. In this respect, it is important to make the distinction between outcomes that represent change, e.g.
improvement, and outcomes that represent a state that is independent of a preceding or baseline evaluation. While both concepts provide important indications regarding the efficacy of a trial intervention on HRQoL, definitions of improvement may be met when the outcome still is unsatisfactory. By contrast, when PROMs denote current states, such as FHS rather than index scores in the case of EQ-5D-3L, such states may be met even when no actual change has occurred, yet still representing desirable conditions and therefore constituting pertinent outcomes. However, it is worth noting that change also captures improvement and worsening from the baseline health profile, which is omitted in the report of a current state. To account for this, we herein present longitudinal FHS perception during the study period before and after adjustment for baseline status.

A finding worth noting was that add-on belimumab 1 mg/kg was associated with a response of “no problems” in the anxiety/depression EQ-5D dimension, whereas no such association was seen for belimumab 10 mg/kg. This observation becomes interesting in light of previous reports of depression, suicidal attempts and self-injury in an open label extension of BLISS-52 and BLISS-76, mainly during the first year of follow-up [34]. Although no firm conclusions can be drawn from these observations, further investigation of potential belimumab-related psychiatric adverse events is warranted, especially in the subset of patients with neuropsychiatric SLE for which data on belimumab use are scarce [35].

In conformity with early reports from the BLISS-52 and BLISS-76 trials demonstrating a beneficial impact of belimumab in various HRQoL aspects [9], we found that belimumab 10 mg/kg favoured EQ-5D-3L FHS perception, also after adjustment for factors with confounding potentiality and within patient subgroups of particular interest; the benefit from belimumab remained evident after adjustment for baseline status. While female sex and increasing BMI were independently negatively associated with FHS after the trial intervention, in line with their known negative impact on HRQoL in SLE patients [36-38], we herein demonstrated that
women benefited from belimumab 10 mg/kg towards FHS perception. Asian ethnicity was associated with FHS after the trial intervention, which contrasts with the generally heavier SLE disease burden in Asians compared with Caucasians [39]; however, this association did not hold true after adjustment for baseline status. In subgroup analysis, African Americans showed a disbenefit in attaining FHS compared with other ancestries, which nevertheless was effaced by the addition of belimumab 10 mg/kg to ST. In agreement with previous findings from observational [40, 41] and clinical trial settings [42, 43] showing a greater benefit from belimumab in patients with minimal or no organ damage, belimumab 10 mg/kg resulted in a higher percentage of FHS respondents at week 52 in patients with no organ damage than among patients with SDI scores >0.

Interestingly, higher proportions of FHS at week 52 were seen in anti-dsDNA positive versus negative patients who received belimumab 10 mg/kg plus ST, but no such difference was observed in patients who received ST alone, in conformity with the previously reported clinical and HRQoL benefit of belimumab in anti-dsDNA positive individuals [44]. The same pattern was seen for anti-Sm positive versus negative patients, which aligns with previous reports of anti-Sm positivity predicting clinical benefit from B cell therapy with belimumab [45] or rituximab [46]. The apparent resemblance between the clinical benefit and the increased probability to experience FHS exerted by belimumab in anti-dsDNA and anti-Sm positive individuals consolidates the known-group validity of EQ-5D-3L FHS and further supports the notion that clinically relevant properties are incorporated in this PROM.

Recently, we reported an association between AMA use and EQ-5D-3L FHS in the same SLE population, however before the trial intervention [47]. We herein demonstrated a similar association following 52 weeks of treatment, which held true in patients given belimumab 10 mg/kg, but not among patients who received placebo. Additionally, we demonstrated a greater benefit from belimumab 10 mg/kg towards FHS when given along with
AMA versus without. Collectively, our findings imply that belimumab and AMA both contribute to full health perception, which is enhanced by their concomitant use. Supportive of this synergy at a mechanistic level were recent reports of decreasing antiphospholipid antibody levels following belimumab and AMA treatment combined, but not belimumab alone [48], especially in SLE patients on long-standing AMA treatment [49]. AMA have been shown to be associated with diminutions of serum levels of B cell activating factor (BAFF) [50, 51], which is, at least partly, explained by downregulation of type I interferon-mediated BAFF production [52]. Along with the direct binding of belimumab to circulating BAFF, this may contribute to additive BAFF neutralisation. As evidence accumulates within molecular and herein HRQoL facets, exploration of mechanisms underlying the synergy between belimumab and AMA is warranted.

The post-hoc nature of our analysis constituted a limitation. Moreover, data on comorbidities with confounding potentiality, e.g. fibromyalgia, as well as socioeconomic status, were unfortunately unavailable. Finally, patients with severe active lupus nephritis or neuropsychiatric lupus were excluded from the trials, and our findings may not apply to these SLE subgroups. Strengths included the large SLE population and extensive longitudinal data, allowing for essential adjustments in statistical analyses. While this study focused on EQ-5D-3L FHS, further investigation of the psychometric properties of EQ-5D in SLE populations has merit. For instance, sensitivity analysis of different index score thresholds could determine less stringent EQ-5D-based definitions with equal or greater discriminative ability in SLE clinical trials. Importantly, since different response patterns may result in similar index scores, such sensitivity analysis should be conducted along with separate analysis for each one of the five EQ-5D dimensions to ensure the clinical relevance of the findings. Finally, acknowledging the clinical heterogeneity of SLE, stratification by disease manifestations is merited in future studies.
Conclusions

In this investigation, EQ-5D-3L FHS displayed ability to discriminate between belimumab and placebo, as well as between responders and non-responders, in two large phase III clinical trials of SLE which both had met their primary endpoints. Using this outcome in subsequent analyses, we corroborated a benefit from belimumab in anti-dsDNA and anti-Sm positive SLE patients, as well as a synergistic effect of AMA when combined with belimumab. Our data consolidate important psychometric properties for EQ-5D-3L FHS, and call for future studies to provide credence for its usefulness in SLE study design.

Funding

This work was supported by the GlaxoSmithKline Investigator-Sponsored Studies (ISS) programme, and grants from the Swedish Rheumatism Association (R-932236), King Gustaf V’s 80-year Foundation (FAI-2019-0635), Professor Nanna Svartz Foundation (2019-00290), Ulla and Roland Gustafsson Foundation (2019-12), Region Stockholm and Karolinska Institutet.

Acknowledgments

The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for sharing the data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials with the Clinical Study Data Request (CSDR) consortium, as well as all participating patients.

Contributors
Conception and design of the work: JL, AG, YE, IP. Data management: JL, AG, AB, SE, DL, JM, MP, FC, IP. Statistical analysis and interpretation of data: JL, AG, DL, FC, YE, EH, MR, IP. Patient research partner: YE. Critical revision of the manuscript for important intellectual content: all authors. All authors reviewed and approved the final version of the manuscript prior to submission, and agree to be accountable for all aspects of the work.

Conflict of interest

IP has received research funding from GlaxoSmithKline and Elli Lilly and Company, and honoraria from Gilead Sciences, GlaxoSmithKline, and Novartis. EH has received honoraria from the EuroQol Research Foundation. The other authors declare that they have no conflicts of interest related to this work.

Ethics

The study complied with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all study participants prior to enrolment in BLISS-52 and BLISS-76. The BLISS study protocols were reviewed and approved by regional ethics review boards for all participating centres, and the study protocol for this post-hoc analysis was reviewed and approved by the Swedish Ethical Review Authority (2019-05498).

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.
References

1 Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? *J Rheumatol* 2005;32(9):1706-8.

2 Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. *Lupus* 2016;25(10):1111-21.

3 Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. *Lupus* 2000;9(5):322-7.

4 Yen JC, Neville C, Fortin PR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. *Lupus* 1999;8(8):660-70.

5 Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.

6 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J Pain Symptom Manage* 1997;13(2):63-74.

7 U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. *Health Qual Life Outcomes* 2006;4:79.

8 Strand V, Simon LS, Meara AS, Touma Z. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematous: a systematic review. *Lupus Sci Med* 2020;7(1).
9 Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. *Ann Rheum Dis* 2014;73(5):838-44.

10 EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.

11 Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. *J Rheumatol* 2009;36(6):1209-16.

12 EuroQol Research Foundation. EQ-5D-3L User Guide. 2018. Available online: https://euroqol.org/publications/user-guides (accessed on 30 July 2020).

13 Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377(9767):721-31.

14 Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum* 2011;63(12):3918-30.

15 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40(9):1725.

16 Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med* 2005;353(24):2550-8.

17 Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29(2):288-91.
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996;39(3):363-9.

Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. *Arthritis Rheum* 2009;61(9):1143-51.

Agency for Healthcare Research and Quality (AHRQ). AHRQ PUF Documentation Files. Available online: [https://meps.ahrq.gov/mepsweb/data_stats/download_data_files_results.jsp?cboDataYear=All&cboDataTypeY=1%2CHousehold+Full+Year+File&buttonYearandDataType=Search&cboPufNumber=All&SearchTitle=Consolidated+Data](https://meps.ahrq.gov/mepsweb/data_stats/download_data_files_results.jsp?cboDataYear=Al l&cboDataTypeY=1%2CHousehold+Full+Year+File&buttonYearandDataType=Search&cboPufNumber=All&SearchTitle=Consolidated+Data) (accessed on 8 August 2020).

Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis* 2016;75(9):1615-21.

Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. *Ann Rheum Dis* 2019;78(5):629-33.

Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. *Expert Opin Biol Ther* 2019;19(2):157-68.

van Vollenhoven R, Voskuyl A, Bertrias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis* 2017;76(3):554-61.

Parodis I, Emamikia S, Gomez A, et al. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. *The Lancet Rheumatology* 2019;1(3):e163-e73.
26 Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. *Lupus* 1998;7(2):101-7.

27 Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? *Lupus* 2004;13(12):924-6.

28 Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. *J Rheumatol* 2001;28(3):525-32.

29 Legge A, Doucette S, Hanly JG. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus. *J Rheumatol* 2016;43(6):1050-6.

30 Duarte C, Abreu P, Couto M, Vaz C, Malcata A, Inês L. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage. *Acta Reumatol Port* 2010;35(1):30-5.

31 Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. *Clin Exp Rheumatol* 1996;14(3):305-8.

32 Hanly JG. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study. *Lupus* 1997;6(3):243-7.

33 Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. *Lupus Sci Med* 2014;1(1):e000031.

34 van Vollenhoven RF, Navarra SV, Levy RA, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. *Rheumatology (Oxford)* 2020;59(2):281-91.
35 Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis* 2012;71(11):1833-8.

36 Gu M, Cheng Q, Wang X, et al. The impact of SLE on health-related quality of life assessed with SF-36: a systematic review and meta-analysis. *Lupus* 2019;28(3):371-82.

37 Zhu LW, Zhang T, Pan HF, Li XP, Ye DQ. BMI, disease activity, and health-related quality-of-life in systemic lupus erythematosus. *Clin Rheumatol* 2010;29(12):1413-7.

38 Gomez A, Hani Butrus F, Johansson P, et al. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. *Rheumatology* 2020.

39 Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. *Nat Rev Rheumatol* 2016;12(10):605-20.

40 Parodis I, Sjowall C, Jonsen A, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. *Autoimmun Rev* 2017;16(4):343-51.

41 Gatto M, Saccon F, Zen M, et al. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. *Arthritis Rheumatol* 2020;72(8):1314-24.

42 Parodis I, Gomez A, Emamikia S, Chatzidionysiou K. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. *Ann Rheum Dis* 2019;78(7):1006-7.

43 Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. *Rheumatology (Oxford)* 2019;58(12):2170-6.
van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. *Ann Rheum Dis* 2012;71(8):1343-9.

Parodis I, Akerstrom E, Sjowall C, et al. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. *Int J Mol Sci* 2020;21(10).

Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. *Ann Rheum Dis* 2008;67(7):1011-6.

Gomez A, Soukka S, Johansson P, et al. Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. *J Clin Med* 2020;9(6).

Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. *Ann Rheum Dis* 2020;79(2):304-7.

Bettiol A, Pregolato F, Sciascia S, Emmi G, Prisco D, Meroni PL. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al. *Ann Rheum Dis* 2020.

Hernandez-Breijo B, Gomez A, Soukka S, Johansson P, Parodis I. Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. *Autoimmun Rev* 2019;18(10):102372.
Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. *Scand J Immunol* 2006;63(4):299-303.

Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020;16(3):155-66.
Figure legends

Figure 1. Ability of EQ-5D-3L full health state to discriminate between belimumab and placebo. Proportions of patients in EQ-5D-3L FHS at baseline and every fourth week in the pooled BLISS study population (A; see Supplementary Table S4 for actual data), the BLISS-52 trial (B; see Supplementary Table S5 for actual data) and the BLISS-76 trial (C; see Supplementary Table S6 for actual data), including stratification by treatment arm. Longitudinal perception of FHS was adjusted for baseline status using logistic regression analysis. Statistically significant differences are denoted by asterisks. FHS: full health state.
Figure 2. Ability of EQ-5D-3L full health state to discriminate between SRI-4 responders and non-responders. Proportions of patients in EQ-5D-3L FHS at baseline and every fourth week among SRI-4 responders versus non-responders in the pooled BLISS study population (A; see Supplementary Table S7 for actual data), the BLISS-52 trial (B; Supplementary Table S8) and the BLISS-76 trial (C; Supplementary Table S9). Bars illustrate the EQ-5D-3L FHS proportions at week 52, and the forest plots illustrate the corresponding ORs (diamonds) and 95% CIs (whiskers). Longitudinal perception of FHS was adjusted for baseline status using
logistic regression analysis. Statistically significant differences are denoted by asterisks. FHS: full health state; OR: odds ratio; SRI-4: SLE Responder Index 4.

Figure 3. Discriminative ability of level 1 response by EQ-5D dimension. Proportions of patients with a level 1 (i.e. “no problems”) response at week 52 across treatment arms (A; see Supplementary Table S10 for actual data) and among SRI-4 responders versus non-responders in the pooled BLISS study population (B; see Supplementary Table S11 for actual data). Comparisons were adjusted for baseline status using logistic regression analysis. Statistically significant differences are denoted by asterisks. SRI-4: SLE Responder Index 4.
Figure 4. Factors associated with EQ-5D-3L full health state at week 52. Forest plot illustrating ORs (diamonds) and 95% CIs (whiskers) deriving from multivariable logistic regression analysis, with EQ-5D-3L FHS at week 52 as the dependent variable. FHS at baseline was included among covariates in the model (not shown). Statistically significant P values are denoted by asterisks. Actual data are presented in Supplementary Table S13. C3: complement component 3; C4 complement component 4; FHS: full health state; OR: odds ratio; SDI: SLICC/ACR Damage Index.
Figure 5. EQ-5D-3L full health state frequencies at week 52 in relation to selected variables. Green bars represent EQ-5D-3L FHS frequencies at week 52 within the entire BLISS study population, stratified by selected binomial variables, i.e. sex (A), Black/African American ancestry versus all other ancestries (B), SDI score >0 versus 0 (C), anti-dsDNA (D), anti-Sm (E) and aCL IgM positivity versus negativity (F), AMA use (G). Grey and blue bars represent FHS frequencies within the placebo and the belimumab 10 mg/kg patient subgroup, respectively. P values are derived from Pearson’s chi-square test, or logistic regression analysis where adjustment for baseline status was applied (comparisons between belimumab and placebo). Statistically significant differences are denoted by asterisks. AMA: antimalarial agents; FHS: full health state; SDI: SLICC/ACR Damage Index.
Table 1. Characteristics of EQ-5D-3L FHS attainers versus non-attainers at week 52 in the pooled BLISS study population.

|                  | All patients | FHS | No FHS | P value |
|------------------|--------------|-----|--------|---------|
|                  | N = 1665     | N = 383 | N = 1282 |
| **Patient characteristics** |              |       |        |         |
| Age at baseline (years) | 37.8 ± 11.5 | 34.2 ± 10.8 | 38.9 ± 11.5 | < 0.001 |
| Female sex | 1566 (94.1%) | 350 (91.4%) | 1216 (94.9%) | 0.012 |
| Ancestries |              |       |        |         |
| Asian | 336 (20.2%) | 115 (30.0%) | 221 (17.2%) | < 0.001 |
| Black/African American | 148 (8.9%) | 22 (5.7%) | 126 (9.8%) | 0.014 |
| Indigenous American* | 383 (23.0%) | 102 (26.6%) | 281 (21.9%) | 0.054 |
| White/Caucasian | 798 (47.9%) | 144 (37.6%) | 654 (51.0%) | < 0.001 |
| Hispanic/Latin American ethnicity | 593 (35.6%) | 148 (38.6%) | 445 (34.7%) | 0.159 |
| **Clinical data** |              |       |        |         |
| SLE duration at baseline (years) | 4.5 (1.5–9.4) | 4.2 (1.3–9.1) | 4.5 (1.5–9.6) | 0.134 |
| Mean BMI (week 0−52) | 25.8 ± 5.9 | 24.2 ± 4.9 | 26.2 ± 6.1 | < 0.001 |
| SLEDAI-2K score |              |       |        |         |
| Baseline | 9.9 ± 3.8 | 9.7 ± 4.0 | 10.0 ± 3.8 | 0.019 |
| Week 52 | 6.2 ± 4.4 | 5.3 ± 3.6 | 6.4 ± 4.5 | < 0.001 |
| SDI score |              |       |        |         |
| Baseline | 0.8 ± 1.2 | 0.5 ± 0.9 | 0.9 ± 1.3 | < 0.001 |
| Week 52 | 0.8 ± 1.3 | 0.5 ± 1.0 | 0.9 ± 1.3 | < 0.001 |
| SDI score > 0 |              |       |        |         |
| Baseline | 705 (42.4%); N = 1664 | 112 (29.2%) | 593 (46.3%); N = 1281 | < 0.001 |
| Week 52 | 740 (44.5%); N = 1664 | 116 (30.3%) | 624 (48.7%); N = 1281 | < 0.001 |
| Serological profile at baseline |              |       |        |         |
| Anti-dsDNA (+) | 1154 (69.3%) | 310 (80.9%) | 844 (65.8%) | < 0.001 |
| Anti-Sm (+) | 523 (31.4%); N = 1663 | 138 (36.1%); N = 382 | 385 (30.1%); N = 1281 | 0.025 |
| Anti-ribosomal P protein (+) | 273 (16.8%); N = 1624 | 74 (19.7%); N = 376 | 199 (15.9%); N = 1248 | 0.090 |
| aCL IgA (+) | 24 (1.4%); N = 1663 | 4 (1.0%); N = 382 | 20 (1.6%); N = 1275 | 0.454 |
| aCL IgG (+) | 369 (22.2%); N = 1663 | 80 (20.9%); N = 382 | 289 (22.6%); N = 1281 | 0.506 |
| aCL IgM (+) | 112 (6.7%); N = 1663 | 22 (5.8%); N = 382 | 90 (7.0%); N = 1281 | 0.080 |
| Low C3 | 747 (44.9%); N = 1664 | 116 (30.3%) | 624 (48.7%); N = 1281 | < 0.001 |
| Low C4 | 935 (56.2%); N = 1664 | 234 (61.1%) | 701 (54.7%); N = 1281 | < 0.001 |
| Prednisone eq. dose (mg/day) |              |       |        |         |
| Baseline | 10.7 ± 8.6 | 11.2 ± 8.8 | 10.6 ± 8.6 | 0.221 |
| Week 52 | 8.8 ± 7.9; N = 1324 | 8.1 ± 6.3; N = 337 | 9.0 ± 8.3; N = 987 | 0.086 |
| AMA at week 52† | 1069 (64.2%) | 267 (69.7%) | 802 (62.6%) | 0.010 |
| Imunosuppressants at week 52 |              |       |        |         |
| Azathioprine | 376 (22.6%) | 106 (27.7%) | 270 (21.1%) | 0.007 |
| Methotrexate | 218 (13.1%) | 45 (11.7%) | 173 (13.5%) | 0.374 |
| Mycophenolic acid | 188 (11.3%) | 42 (11.0%) | 146 (11.4%) | 0.819 |
| Other immunosuppressants‡ | 33 (2.0%) | 6 (1.6%) | 27 (2.1%) | 0.506 |
| Trial intervention |              |       |        |         |
| Placebo | 558 (33.5%) | 108 (28.2%) | 450 (35.1%) | 0.012 |
| BLM 1 mg/kg | 555 (33.3%) | 131 (34.2%) | 424 (33.1%) | 0.681 |
| BLM 10 mg/kg | 552 (33.2%) | 144 (37.6%) | 408 (31.8%) | 0.035 |
| SRI-4 at week 52 | 745 (44.7%) | 201 (52.5%) | 544 (42.4%) | 0.001 |

Data are presented as number (percentage) or mean ± SD. In case of non-normal distributions, the median (interquartile range) is indicated. In case of missing values, the total number of patients with available data is indicated. Statistically significant P values are in bold.

* Alaska Native or American Indian from North, South or Central America.
† Hydroxychloroquine, chloroquine, mepacrine, mepacrine hydrochloride or quinine sulfate.
‡ Cyclosporine, oral cyclophosphamide, leflunomide, mizoribine or thalidomide.

AMA: antimalarial agents; BLM: belimumab; C3: complement component 3; C4: complement component 4; FHS: full health state; SDI: SLICC/ACR Damage Index; Sm: Smith; SRI-4: SLE Responder Index 4.